Literature DB >> 25460827

Prostaglandin E2 switches from a stimulator to an inhibitor of cell migration after epithelial-to-mesenchymal transition.

Ying-Ji Li1, Nobuhiro Kanaji2, Xing-Qi Wang3, Tadashi Sato4, Masanori Nakanishi5, Miok Kim6, Joel Michalski7, Amy J Nelson7, Maha Farid7, Hesham Basma7, Amol Patil7, Myron L Toews8, Xiangde Liu7, Stephen I Rennard9.   

Abstract

Epithelial-mesenchymal transition (EMT) is critical for embryonic development, and this process is recapitulated in adults during wound healing, tissue regeneration, fibrosis and cancer progression. Cell migration is believed to play a key role in both normal wound repair and in abnormal tissue remodeling. Prostaglandin E2 (PGE2) inhibits fibroblast chemotaxis, but stimulates chemotaxis in airway epithelial cells. The current study was designed to explore the role of PGE2 and its four receptors on airway epithelial cell migration following EMT using both the Boyden blindwell chamber chemotaxis assay and the wound closure assay. EMT in human bronchial epithelial cells (HBECs) was induced by TGF-β1 and a mixture of cytokines (IL-1β, TNF-α, and IFN-γ). PGE2 and selective agonists for all four EP receptors stimulated chemotaxis and wound closure in HBECs. Following EMT, the EP1 and EP3 agonists were without effect, while the EP2 and EP4 agonists inhibited chemotaxis as did PGE2. The effects of the EP2 and EP4 receptors on HBEC and EMT cell migration were further confirmed by blocking the expected signaling pathways. Taken together, these results demonstrate that PGE2 switches from a stimulator to an inhibitor of cell migration following EMT of airway epithelial cells and that this inhibition is mediated by an altered effect of EP2 and EP4 signaling and an apparent loss of the stimulatory effects of EP1 and EP3. Change in the PGE2 modulation of chemotaxis may play a role in repair following injury.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotaxis, Tissue repair; Epithelial–mesenchymal transition; PGE(2)

Mesh:

Substances:

Year:  2014        PMID: 25460827     DOI: 10.1016/j.prostaglandins.2014.10.003

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  6 in total

1.  Can GPCRs Be Targeted to Control Inflammation in Asthma?

Authors:  Pawan Sharma; Raymond B Penn
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Host knockout of E-prostanoid 2 receptors reduces tumor growth and causes major alterations of gene expression in prostaglandin E2-producing tumors.

Authors:  Annika Gustafsson Asting; Britt-Marie Iresjö; Camilla Nilsberth; Ulrika Smedh; Kent Lundholm
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

Review 3.  Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease.

Authors:  Abigail Basson; Ashley Trotter; Alex Rodriguez-Palacios; Fabio Cominelli
Journal:  Front Immunol       Date:  2016-08-02       Impact factor: 7.561

4.  Modulation by 17,20S(OH)2pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis.

Authors:  Monica L Brown Lobbins; Andrzej T Slominski; Karen A Hasty; Sicheng Zhang; Duane D Miller; Wei Li; Tae-Kang Kim; Zorica Janjetovic; Robert C Tuckey; Imara-Safi O Scott; Linda K Myers; Arnold E Postlethwaite
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

5.  The role of altered fatty acid in pathological scars and their dermal fibroblasts.

Authors:  Jin-Xiu Yang; Shi-Yi Li; Min-Liang Chen; Le-Ren He
Journal:  Chin J Traumatol       Date:  2022-04-02

6.  Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition.

Authors:  Sepp R Jansen; Wilfred J Poppinga; Wim de Jager; Frank Lezoualc'h; Xiaodong Cheng; Thomas Wieland; Stephen J Yarwood; Reinoud Gosens; Martina Schmidt
Journal:  Oncotarget       Date:  2016-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.